Clinical trial
A Single-center, Open Study Evaluating Efficacy and Safety of XLCART001（CD-19） Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects
NCT03598179 is registered in ClinicalTrials.gov with The First Affiliated Hospital with Nanjing Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-center, Open Study Evaluating Efficacy and Safety of XLCART001（CD-19） Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- June 1, 2018
- Completion date
- July 1, 2020
- Enrollment
- 10 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.